Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 6779-6788

  Zhou, Xiaoyan ^a,b   Tan, Ming ^a   Hawthorne, Valerie Stone ^a   Klos, Kristine S ^a   Lan, Keng Hsueh ^a   Yang, Ying ^a   Yang, Wentao ^b   Smith, Terry L ^a   Shi, Daren ^b   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INHIBITOR PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER GROWTH; CANCER INVASION; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FIBROADENOMA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SENSITIVITY ANALYSIS; SURVIVAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARRIER PROTEINS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 6044223545     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0112     Document Type: Article

References (44)

1. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 1997;75:429-39.
2. Borg A, Ferno M, Peterson C. Predicting the future of breast cancer. Nat Med 2003;9:16-8.
3. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature (Lond) 2001;411:355-65.
4. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-26.
5. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003;3:371-7.
6. Chen J, Fang Y. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 2002;64:1071-7.
7. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003;2:S169-77.
8. Pyronnet S, Sonenberg N. Cell-cycle-dependent translational control. Curr Opin Genet Dev 2001;11:13-8.
9. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62.
10. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002;3:295-304.
11. Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003;4:126-37.
12. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002;86:540-5.
13. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000;275:8027-31.
14. Schmitz KJ, Otterbach F, Callies R, et al. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 2004;17:15-21.
15. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-21.
16. Zhou BP, Liao Y, Xia W, et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-82.
17. Stoica GE, Franke TF, Wellstein A, et al. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 2003:22:2073-87.
18. Stoica GE, Franke TF, Moroni M, et al. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003;22:7998-8011.
19. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
20. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-58.
21. Sellappan S, Grijalva R, Zhou X, et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004;64:3479-85.
22. Yang W, Klos KS, Zhou X, et al. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 Overexpression and with p21Cip1 overexpression. Cancer (Phila) 2003;98:1123-30.
23. Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996;13:1359-65.
24. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993;24:85-95.
25. Cdc2 activation and is involved in resistance to Taxol-induced apoptosis. Mol Cell 2002;9:993-1004.
26. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997;57:1199-205.
27. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95.
28. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
29. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999;344:427-31.
30. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000;60:3504-13.
31. Scott PH, Lawrence JC Jr. Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes. J Biol Chem 1998;273:34496-501.
32. 2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 2002;277:17657-62.
33. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (Wash DC) 1997;277:99-101.
34. Yu D, Jing T, Liu B, et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581-91.
35. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature (Lond) 2000;407:538-41.
36. Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003;30:38-48.
37. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 2002;12:319-28.
38. Gago FE, Tello OM, Diblasi AM, Ciocca DR. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients. J Steroid Biochem Mol Biol 1998;67:431-7.
39. Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 2003;9:2882-6.
40. Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA 2001;98:7037-44.
41. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002;277:23977-80.
42. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001;98:10314-9.
43. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62:5027-34.
44. Fairclough DL, Gagnon DD, Zagari MJ, Marschner N, Dicato M. Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alpha in anemic cancer patients. Qual Life Res 2003;12:1013-27.